PDCD1 and hypophysitis: Compared to PD-1/PD-L1 inhibitors, CTLA4-inhibitors frequently cause colitis (irAE-GI), hypophysitis, and dermatitis (irAE-skin), and less frequently, cause pneumonitis (irAE-lung), hypothyroidism, and skeletal symptoms such as myalgias and arthralgias (21, 22).